Ecstasy Assay Launched by Beckman Coulter
A new system to assess patients for the presence of ecstasy, the DRI Ecstasy, was recently launched (pdf) by Beckman Coulter, Incorporated. Beckman posted an overview of the new assay on their website.
With the new assay, clinicians can semi-quantitatively and qualitatively assess the presence of ecstasy in human urine. The test is a simplified and rapid analytical screening test with a cutoff point of 500 ng/mL. The DRI Ecstasy test uses a specific antibody that detects the presence of ecstasy with minimal cross-reactivity to other amphetamine compounds. The test employs ready-to-use liquid reagents and calibrators.
Using the recommended system from Beckman, labs can produce a qualitative, interpretative report. This allows clinicians to compare patient test data from the cut-off value. The test findings include either positive or negative results; negating the need for interpretation of findings. The test can provide an estimate of the ecstasy concentration in the urine with five calibrator level. Positive test results, importantly, should be confirmed with an alternative test approach.
The system works in cooperation with the Synchron and UniCelDxC chemistry systems available from Beckman. The test is targeted for healthcare facilities with mid- to large-volume. Using that system, the test has 95 percent sensitivity at 46 ng/mL.
January 18, 2008 Related topics: Product Launches, Laboratory Equipment, Diagnostic, Emergency